started on second-line docetaxel (75 mg/m 2 ) and nintedanib (200 mg twice a day) (every 3 weeks)-based palliative chemotherapy. After 6 cycles, the patient had a clinical response as well as partial response as per the PERCIST criteria on re-evaluation with positron emission tomography-CT scan. However, after 1 month, the patient presented with altered behavior, and imaging revealed rapidly progressive disease in the lung and the mediastinum compared to previous imaging. Brain magnetic resonance imaging (MRI) revealed miliary dissemination in the brain [ Figure 3 ]. The patient refused further treatment and opted for best supportive care. She succumbed to the disease, about after 11 months of initiating treatment.
DISCUSSION
Lung cancer was traditionally a disease of old smoker men; however, recently, the trend is shifting to young nonsmoker women, particularly in Asia. [3] The common radiological presentation includes a lung mass with associated metastasis. However, presentation as a miliary mottling on chest X-ray and miliary brain metastases (also known as carcinomatous encephalitis) is atypical and rarely reported. [4, 5] Miliary brain metastases are an extremely rare form of brain metastasis characterized by the presence of tumor spreading into the perivascular Virchow-Robin spaces, parenchyma, and meninges. Generally seen as an advanced stage of the primary disease, this form of dissemination arises most often from lung adenocarcinoma [5] [6] [7] typically detected by MRI examinations.
In the present case, a female nonsmoker patient with tested driver mutation-negative lung adenocarcinoma developed miliary brain metastases involving gray matter, while on therapy. Lung adenocarcinomas with miliary metastases are usually unresponsive to the platinum-based therapy. We initially treated the patient with pemetrexed-based therapy to which she failed to respond and progressed. To best of our knowledge, this is the first case of lung adenocarcinomas with miliary metastases treated with docetaxel and nintedanib. It appears that our patients benefited from nintedanib therapy, as she showed a partial response with a 5-month progression-free survival following its introduction.
INTRODUCTION
Miliary mottling on chest X-ray is a well-known entity, usually associated with infectious etiologies such as tuberculosis, histoplasmosis, mycoplasma, nocardia, and blastomycosis. There may also be immune and inflammatory disorders such as sarcoidosis, tropical pulmonary eosinophilia, and hypersensitivity pneumonitis. Noninfectious causes include pneumoconioses such as silicosis and pulmonary hemosiderosis. [1, 2] Rarely, there may be a malignant cause of miliary mottling like hematogenous metastases from carcinoma of the thyroid and kidney or lymphangitic carcinomatosis and may even be primary lung cancer. [3] However, the suspicion of malignancy for patients with miliary mottling remains low, especially in a developing country like India, where tuberculosis is the most common cause. Here is a similar case of a young woman with miliary lung nodules diagnosed as adenocarcinoma of the lung.
CASE REPORT
A 37-year-old female previously healthy, nonsmoker, presented to a primary physician with a history of cough and chest pain of month duration. She was evaluated and started on oral antibiotics with no response to therapy over 2 weeks. On further evaluation, chest X-ray was suggestive of miliary mottling, and sputum was negative for acid-fast bacilli. The patient was subsequently put on empirical antituberculosis therapy. The patient over the next 2 weeks had persistent symptoms and was further evaluated where computed tomography (CT) scan of the chest revealed a left lung lesion with bony and lymph node involvements with bilateral miliary lung nodules and left pleural and pericardial effusion [ Figure 1 ]. However, a CT-guided biopsy revealed a pathological diagnosis of non-small cell lung carcinoma, morphologically favoring adenocarcinoma (solid, micropapillary, and acinar pattern) [ Figure 2 ]. Subsequently, on further workup, immunohistochemistry showed positivity for thyroid transcription factor 1. Mutational analysis revealed no epidermal growth factor receptor mutation, or rearrangement anaplastic lymphoma kinase, ROS, and MET were wild type. The patient was started on pemetrexed (500 mg/m 2 ) plus carboplatin (area under the curve: 5) (every 3 weeks)-based palliative chemotherapy. The patient had a progressive disease after three cycles of chemotherapy and was subsequently
Case Letters
A rare case of lung adenocarcinoma: Unusual presentation with miliary mottling brain metastases are usually silent and differ from patient to patient [7] and may show an atypical clinical course and atypical symptoms. The authors reported convulsion, hemiparesis, memory disturbance, psychiatric symptoms and disorientation as primary symptoms of miliary brain metastasis. [6] The practice of starting empirical ATT for patients with miliary mottling on imaging delays the actual cancer treatment.
Few cases of miliary primary lung carcinoma with miliary brain metastasis are reported in the literature. [3] [4] [5] 8] Owing to its rarity, clinicians should be vigilant about the possibility of miliary mottling on chest X-ray to be malignant.
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Nil. Gefitinib-induced pyogenic granuloma in a patient with lung cancer Sir, Gefitinib, a tyrosine kinase inhibitor (TKI), is commonly used as first-line targeted therapy in adenocarcinoma of the lung with epidermal growth factor receptor (EGFR) exon 19 and 21 mutation. It interrupts signaling through the EGFR in the target cells. We report a case of lung cancer treated with gefitinib, who developed a pyogenic granuloma at 4 months.
A 39-year-old nonsmoker male was diagnosed with advanced-stage adenocarcinoma of the lung with EGFR exon 19 deletion mutation. After being started on daily 250 mg gefitinib for 4 months, he achieved a partial response (significant resolution of his lung mass and metastatic lesions). However, he noticed a small friable pinkish painless growth in the nail plate junction and lateral nail beds of fingers and right toe. It was associated with mild pigmentary change and powdery scaling [ Figure 1 ]. The patient denied a history of trauma to the fingers or toes before the development of lesion or in the recent past. There was no history suggestive of invasive procedure in the recent past. Examination of the skin and mucosa did not reveal any other lesions on the body. Based on history and examination, a provisional diagnosis of gefitinib-induced pyogenic granuloma with nail fold dermatitis was made, and the patient was counseled to continue gefitinib as the benefits clearly outweighed the risks. EGFR TKIs are known for their skin adverse effects causing pyogenic granuloma but are very uncommon. Other cutaneous adverse effects due to EGFR TKIs include acneiform eruption, xerosis, hyperpigmentation, dry skin, rash, telangiectasia, and paronychia. [1] Gefitinib binds to the adenosine triphosphate-binding site of the EGFR tyrosine kinase enzyme, thereby inhibiting the activation of antiapoptotic signal transduction cascade, and results in uncontrolled cell proliferation. This effect of the drug may result in pyogenic granuloma. Other drugs documented to cause pyogenic granuloma include systemic retinoids, anti-EGFR monoclonal antibodies such as cetuximab; antineoplastic agents such as capecitabine, docetaxel, and 5-fluorouracil; and antiretroviral agents such as indinavir. [2] EGFR positivity is seen in about 40% of Asian population, particularly more common in females and nonsmokers. Hence, the use of gefitinib has been increased in India, and physicians used to encounter such side effect frequently in patients receiving gefitinib. Reported gefitinib-induced pyogenic granuloma from all over the world is about 25 cases. This is probably the first reported case from India.
Granuloma pyogenicum, a polypoid form of capillary hemangioma, is due to tissue reaction seen after repeated insults. Initial inflammation is confined to nail fold, and later, it develops a pyogenic granuloma (i.e., a pedunculated granulomatous tissue) commonly at the great toes. This may get superinfected at the later stages. [3] The average time from the starting of gefitinib and the appearance of pyogenic granuloma is 60 days (2 months). Treatment includes cleaning, wet dressings, and protection from trauma and superadded infection. Padding, use of protected shoes used to avoid pressure on affected nail, and topical or systemic antimicrobials may help from infections in such cases.
A l t h o u g h u n c o m m o n l y r e p o r t e d , a p p r o p r i a t e interpretation of the pathogenicity and the case management of the patient is utmost important in such cases. We report this case to bring awareness among the physicians about pyogenic granuloma in patients treated with gefitinib.
